The short answer
Magnesium levels should be assessed and low values corrected as part of bedaquiline’s heart-rhythm safety plan. This does not mean bedaquiline routinely depletes magnesium or that everyone needs a supplement.
What this answer covers
Serum magnesium assessment and clinician-directed replacement when needed; oral salts, diet and intravenous replacement are not interchangeable.
- Supplement or preparation
- Magnesium
- Medication ingredient
- bedaquiline
Low electrolytes increase the rhythm concern
SIRTURO can prolong the QT interval. The label identifies low potassium, magnesium or calcium as risk factors and calls for assessment and correction of abnormalities as part of treatment safety.
Monitoring is different from a nutrient requirement
The recommendation is to identify and correct low levels. It does not establish that bedaquiline causes depletion in every patient or define a routine supplement dose for someone with normal values.
The whole treatment plan matters
Other QT-prolonging medicines, kidney function, illness and the reason for an electrolyte abnormality affect management. The salt, dose and route of replacement should be chosen for the person’s clinical situation.
Follow the prescribed testing plan
Keep the scheduled blood tests and ECG assessments and discuss supplements with the TB team. No special nutrient-to-bedaquiline spacing interval was established. Fainting or a new abnormal heartbeat warrants urgent assessment.
Evidence and practical considerations
Timing & monitoring
Exact SIRTURO label supports electrolyte assessment/correction for QT safety, not universal depletion or supplementation. Need depends on measured low values and risk; no arbitrary dose or spacing.
- Exact scope
- Serum magnesium assessment and clinician-directed replacement when needed; oral salts, diet and intravenous replacement are not interchangeable. with Bedaquiline fumarate oral SIRTURO tablets, strength expressed as bedaquiline.
- Medication form and route
- oral medication; oral supplement
What remains uncertain
- No unmeasured pair incidence, blanket class transfer or arbitrary spacing interval.
Factors that may matter: Preparation; Dose; Other medicines; Organ function.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 11, 2026
Population: People prescribed bedaquiline
QT prolongation; assess and correct low potassium/calcium/magnesium. Avoid other hepatotoxic exposures; monitor liver function. Avoid strong/moderate CYP3A4 inducers.
How this applies: Exact bedaquiline RxCUI 1364504 IN, with stated salt/formulation/route bridge.
Exact route and formulation apply. Label precautions do not quantify untested botanical pairs or support arbitrary supplement doses.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Research summary published | |
| Article prepared | |
| Prepared exact bedaquiline article with formulation-specific evidence and uncertainty. |
Article revision: 13a32ca5be7d7ae1
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.